Next Article in Journal
Transcriptomic Changes in Medicago truncatula and Lotus japonicus Root Nodules during Drought Stress
Next Article in Special Issue
Effective Treatment of Diabetic Cardiomyopathy and Heart Failure with Reconstituted HDL (Milano) in Mice
Previous Article in Journal
Antiproliferative and Cytotoxic Activity of Xanthohumol and Its Non-Estrogenic Derivatives in Colon and Hepatocellular Carcinoma Cell Lines
Previous Article in Special Issue
Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk
Open AccessArticle

Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease

1
Department of Clinical Chemistry, Medical University of Gdańsk, 80-210 Gdańsk, Poland
2
Clinic & Chair of Nephrology, Transplantology and Internal Diseases, Medical University of Gdańsk, 80-210 Gdańsk, Poland
3
1st Department of Cardiology, Medical University of Gdańsk, 80-210 Gdańsk, Poland
4
Laboratory of Molecular and Cellular Nephrology, Mossakowski Medical Research Centre Polish Academy of Sciences, 80-210 Gdańsk, Poland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(5), 1202; https://doi.org/10.3390/ijms20051202
Received: 7 February 2019 / Revised: 6 March 2019 / Accepted: 6 March 2019 / Published: 9 March 2019
In chronic kidney disease (CKD), the level of high-density lipoprotein (HDL) decreases markedly, but there is no strong inverse relationship between HDL-cholesterol (HDL-C) and cardiovascular diseases. This indicates that not only the HDL-C level, but also the other quantitative changes in the HDL particles can influence the protective functionality of these particles, and can play a key role in the increase of cardiovascular risk in CKD patients. The aim of the present study was the evaluation of the parameters that may give additional information about the HDL particles in the course of progressing CKD. For this purpose, we analyzed the concentrations of HDL containing apolipoprotein A-I without apolipoprotein A-II (LpA-I), preβ1-HDL, and myeloperoxidase (MPO), and the activity of paraoxonase-1 (PON-1) in 68 patients at various stages of CKD. The concentration of HDL cholesterol, MPO, PON-1, and lecithin-cholesterol acyltransferase (LCAT) activity were similar in all of the analyzed stages of CKD. We did not notice significant changes in the LpA-I concentrations in the following stages of CKD (3a CKD stage: 57 ± 19; 3b CKD stage: 54 ± 15; 4 CKD stage: 52 ± 14; p = 0.49). We found, however, that the preβ1-HDL concentration and preβ1-HDL/LpA-I ratio increased along with the progress of CKD, and were inversely correlated with the estimated glomerular filtration rate (eGFR), even after adjusting for age, gender, triacylglycerols (TAG), HDL cholesterol, and statin therapy (β = −0.41, p < 0.001; β = −0.33, p = 0.001, respectively). Our results support the earlier hypothesis that kidney disease leads to the modification of HDL particles, and show that the preβ1-HDL concentration is significantly elevated in non-dialyzed patients with advanced stages of CKD. View Full-Text
Keywords: high-density lipoproteins; chronic kidney disease; atherosclerosis high-density lipoproteins; chronic kidney disease; atherosclerosis
Show Figures

Graphical abstract

MDPI and ACS Style

Kuchta, A.; Ćwiklińska, A.; Czaplińska, M.; Wieczorek, E.; Kortas-Stempak, B.; Gliwińska, A.; Dąbkowski, K.; Sałaga-Zaleska, K.; Mickiewicz, A.; Dębska-Ślizień, A.; Król, E.; Jankowski, M. Plasma Levels of Preβ1-HDL Are Significantly Elevated in Non-Dialyzed Patients with Advanced Stages of Chronic Kidney Disease. Int. J. Mol. Sci. 2019, 20, 1202.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop